GenMark Prices 7M Shares Offering; Stock Soars | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics has priced its public offering of nearly 7.1 million shares of common stock at $4.25 per share.

The Carlsbad, Calif.-based molecular diagnostics firm said that it expects net proceeds from the offering to be roughly $27.6 million. If the underwriters exercise the over-allotment option of nearly 1.1 million shares, the firm's net proceeds will be approximately $31.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.